Skip to content
Screener

Replimune Group REPL Cash & Equivalents

Cash & Equivalents at other companies

Amgen logo
AmgenAMGN
$574M+5.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.47B+22.3%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$194.83M+111%
Regenxbio logo
RegenxbioRGNX
$36.49M-54.1%
Immunome logo
ImmunomeIMNM
$582.69M+126%
CG Oncology logo
CG OncologyCGON
$19.64M+34.3%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+160%
Enterprise value$967.91M+162%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemNine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Effect of exchange rate changes on cash, cash equivalents and restricted cash1,062(125)
Net increase in cash, cash equivalents and restricted cash11,83397,788
Cash, cash equivalents and restricted cash at beginning of period112,82276,157
Cash, cash equivalents and restricted cash at end of period$124,655$173,945
Supplemental disclosure of cash flow information:
Cash paid during the period for interest3,1753,157
Cash paid for income taxes, net125105
Supplemental disclosure of non-cash investing and financing activities:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's cash & equivalents?
Replimune Group (REPL) reported cash & equivalents of $124.66M in Q4 2025.
How has Replimune Group's cash & equivalents changed year-over-year?
Replimune Group's cash & equivalents decreased by 28.3% year-over-year, from $173.95M to $124.66M.
What is the long-term trend for Replimune Group's cash & equivalents?
Over 4 years (2021 to 2025), Replimune Group's cash & equivalents has grown at a -11.5% compound annual growth rate (CAGR), from $184.15M to $112.82M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Replimune Group's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude